9IXZ image
Deposition Date 2024-07-29
Release Date 2025-03-19
Last Version Date 2025-08-13
Entry Detail
PDB ID:
9IXZ
Title:
human KCNQ2-CaM-Ebio3 Complex in the Presence of PIP2
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.20 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Isoform 3 of Potassium voltage-gated channel subfamily KQT member 2
Gene (Uniprot):KCNQ2
Chain IDs:A, B, C, D
Chain Length:611
Number of Molecules:4
Biological Source:Homo sapiens
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Calmodulin-1
Gene (Uniprot):CALM1
Chain IDs:E, F, G, H
Chain Length:149
Number of Molecules:4
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Small molecule inhibits KCNQ channels with a non-blocking mechanism.
Nat.Chem.Biol. 21 1100 1109 (2025)
PMID: 39814994 DOI: 10.1038/s41589-024-01834-8

Abstact

Voltage-gated ion channels (VGICs) are crucial targets for neuropsychiatric therapeutics owing to their role in controlling neuronal excitability and the established link between their dysfunction and neurological diseases, highlighting the importance of identifying modulators with distinct mechanisms. Here we report two small-molecule modulators with the same chemical scaffold, Ebio2 and Ebio3, targeting a potassium channel KCNQ2, with opposite effects: Ebio2 acts as a potent activator, whereas Ebio3 serves as a potent and selective inhibitor. Guided by cryogenic electron microscopy, patch-clamp recordings and molecular dynamics simulations, we reveal that Ebio3 attaches to the outside of the inner gate, employing a unique non-blocking inhibitory mechanism that directly squeezes the S6 pore helix to inactivate the KCNQ2 channel. Ebio3 also showed efficacy in inhibiting currents of KCNQ2 pathogenic gain-of-function mutations, presenting an avenue for VGIC-targeted therapies. Overall, these findings contribute to the understanding of KCNQ2 inhibition and provide insights into developing selective, non-blocking VGIC inhibitors.

Legend

Protein

Chemical

Disease

Primary Citation of related structures